BR112023005987A2 - Composição farmacêutica, preparação farmacêutica, método de tratamento de uma doença ou disfunção associada à atividade de kdm1a em um paciente com sua necessidade, método de inibição de kdm1a e método para suprimir a proliferação de células mieloides malignas em um sujeito com sua necessidade - Google Patents
Composição farmacêutica, preparação farmacêutica, método de tratamento de uma doença ou disfunção associada à atividade de kdm1a em um paciente com sua necessidade, método de inibição de kdm1a e método para suprimir a proliferação de células mieloides malignas em um sujeito com sua necessidadeInfo
- Publication number
- BR112023005987A2 BR112023005987A2 BR112023005987A BR112023005987A BR112023005987A2 BR 112023005987 A2 BR112023005987 A2 BR 112023005987A2 BR 112023005987 A BR112023005987 A BR 112023005987A BR 112023005987 A BR112023005987 A BR 112023005987A BR 112023005987 A2 BR112023005987 A2 BR 112023005987A2
- Authority
- BR
- Brazil
- Prior art keywords
- need
- kdm1a
- disease
- proliferation
- suppressing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086353P | 2020-10-01 | 2020-10-01 | |
| PCT/US2021/053141 WO2022072811A1 (en) | 2020-10-01 | 2021-10-01 | Pharmaceutical formulations for treating diseases mediated by kdm1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023005987A2 true BR112023005987A2 (pt) | 2023-05-02 |
Family
ID=80951023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023005987A BR112023005987A2 (pt) | 2020-10-01 | 2021-10-01 | Composição farmacêutica, preparação farmacêutica, método de tratamento de uma doença ou disfunção associada à atividade de kdm1a em um paciente com sua necessidade, método de inibição de kdm1a e método para suprimir a proliferação de células mieloides malignas em um sujeito com sua necessidade |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230293495A1 (https=) |
| EP (1) | EP4221704B1 (https=) |
| JP (1) | JP7848195B2 (https=) |
| KR (1) | KR20230079151A (https=) |
| CN (1) | CN116367831A (https=) |
| AU (1) | AU2021351536A1 (https=) |
| BR (1) | BR112023005987A2 (https=) |
| CA (1) | CA3193661A1 (https=) |
| MX (1) | MX2023003783A (https=) |
| WO (1) | WO2022072811A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962488A (en) * | 1998-04-08 | 1999-10-05 | Roberts Laboratories, Inc. | Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives |
| US20060089387A1 (en) * | 2004-10-26 | 2006-04-27 | Le Huang | Stabilized pharmaceutical composition comprising antidiabetic agent |
| TW201431552A (zh) | 2008-07-28 | 2014-08-16 | Takeda Pharmaceutical | 醫藥組成物 |
| US20100273825A1 (en) * | 2009-03-30 | 2010-10-28 | Astellas Pharma Inc. | Solid pharmaceutical composition containing solifenacin amorphous form |
| RU2627471C2 (ru) * | 2011-09-14 | 2017-08-08 | Селджин Корпорейшн | Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты |
| WO2015170237A1 (en) * | 2014-05-05 | 2015-11-12 | Torrent Pharmaceuticals Limited | Stable solifenacin composition |
| CA2976350C (en) * | 2015-02-12 | 2023-09-19 | Hugh Young Rienhoff, Jr. | Kdm1a inhibitors for the treatment of disease |
| US20190070172A1 (en) * | 2015-11-05 | 2019-03-07 | Imago Biosciences, Inc. | Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms |
| TWI833686B (zh) | 2016-04-22 | 2024-03-01 | 美商英塞特公司 | Lsd1 抑制劑之調配物 |
| CN111194306B (zh) * | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| KR20220113753A (ko) * | 2019-12-09 | 2022-08-16 | 이마고 바이오사이언시즈 인코포레이티드 | 골수증식성 신생물의 치료를 위한 리신-특이적 히스톤 데메틸라제 억제제 |
-
2021
- 2021-10-01 CN CN202180068111.4A patent/CN116367831A/zh active Pending
- 2021-10-01 MX MX2023003783A patent/MX2023003783A/es unknown
- 2021-10-01 EP EP21876583.2A patent/EP4221704B1/en active Active
- 2021-10-01 CA CA3193661A patent/CA3193661A1/en active Pending
- 2021-10-01 BR BR112023005987A patent/BR112023005987A2/pt unknown
- 2021-10-01 KR KR1020237014383A patent/KR20230079151A/ko active Pending
- 2021-10-01 JP JP2023519794A patent/JP7848195B2/ja active Active
- 2021-10-01 AU AU2021351536A patent/AU2021351536A1/en active Pending
- 2021-10-01 WO PCT/US2021/053141 patent/WO2022072811A1/en not_active Ceased
-
2023
- 2023-03-23 US US18/188,578 patent/US20230293495A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116367831A (zh) | 2023-06-30 |
| WO2022072811A1 (en) | 2022-04-07 |
| EP4221704A1 (en) | 2023-08-09 |
| KR20230079151A (ko) | 2023-06-05 |
| MX2023003783A (es) | 2023-04-26 |
| EP4221704A4 (en) | 2024-11-06 |
| EP4221704B1 (en) | 2025-09-24 |
| JP2023544327A (ja) | 2023-10-23 |
| US20230293495A1 (en) | 2023-09-21 |
| JP7848195B2 (ja) | 2026-04-20 |
| CA3193661A1 (en) | 2022-04-07 |
| AU2021351536A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023005987A2 (pt) | Composição farmacêutica, preparação farmacêutica, método de tratamento de uma doença ou disfunção associada à atividade de kdm1a em um paciente com sua necessidade, método de inibição de kdm1a e método para suprimir a proliferação de células mieloides malignas em um sujeito com sua necessidade | |
| Van Eps et al. | Continuous digital hypothermia initiated after the onset of lameness prevents lamellar failure in the oligofructose laminitis model | |
| Welschinger et al. | Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice | |
| KR100343314B1 (ko) | 만성통증치료에유용한레보부피바카인 | |
| JP2005502643A5 (https=) | ||
| Mattson et al. | Intraosseous gentamicin perfusion of the distal metacarpus in standing horses | |
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| BR0212078A (pt) | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto | |
| BR112015010063A2 (pt) | método para o tratamento ou prevenção de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, utilização de um composto de fórmula (i), um derivado da colquicina conhecido e/ou um sal do mesmo, composição para a prevenção ou tratamento de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, método e regime para reduzir ou prevenir a inflamação induzida por cristal de colesterol no interior das placas ateroscleróticas em um sujeito, regime para o tratamento ou prevenção de um acidente cardiovascular em um indivíduo | |
| US20200405692A1 (en) | Use of isoxazoline compounds for treating demodicosis | |
| KR102059027B1 (ko) | Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물 | |
| BR112023025863A2 (pt) | Métodos para tratar doença pulmonar obstrutiva crônica (dpoc), para reduzir a frequência de exacerbações moderadas a graves em um paciente com dpoc, para tratar ou prevenir dpoc, para manter e/ou melhorar a função pulmonar, para melhorar a contagem de linha de base de eosinófilos no sangue, kit, antagonistas de st2 e anticorpo anti-st2 | |
| MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
| JP2021502392A5 (https=) | ||
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| PH12021550170A1 (en) | Pharmaceutical dosage form which can be adminitered orally and has modified release | |
| Moore et al. | When hydromorphone is not working, try loratadine: an emergency department case of loratadine as abortive therapy for severe pegfilgrastim-induced bone pain | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| Alkeraye et al. | The addition of montelukast for the treatment of chronic idiopathic urticaria | |
| Dhamija et al. | Deferasirox in Indian children with thalassemia major: 3 years experience | |
| US20240261279A1 (en) | Method for treating lung cancer | |
| Katsambas et al. | Itraconazole in the treatment of tinea corporis and tinea cruris | |
| Sharma et al. | Comparison of pethidine and tramadol for the control of shivering in patients undergoing elective surgery under spinal anesthesia | |
| BR112022009716A2 (pt) | Dosagem de um inibidor de tirosina quinase de bruton | |
| KR101985087B1 (ko) | 사비넨을 포함하는 골격근 위축 또는 근육감소증의 예방 또는 치료용 조성물 |